Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Fuji
Fish and Richardson
Accenture
Cipla
Colorcon
Johnson and Johnson
Harvard Business School
Cantor Fitzgerald
Moodys

Generated: October 21, 2017

DrugPatentWatch Database Preview

ZYKADIA Drug Profile

« Back to Dashboard

What is the patent landscape for Zykadia, and when can generic versions of Zykadia launch?

Zykadia is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are twelve patents protecting this drug.

This drug has three hundred and fifty-nine patent family members in fifty-four countries and seventeen supplementary protection certificates in ten countries.

The generic ingredient in ZYKADIA is ceritinib. One supplier is listed for this compound. Additional details are available on the ceritinib profile page.

Summary for Tradename: ZYKADIA

US Patents:12
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list45
Clinical Trials: see list5
Patent Applications: see list29
Drug Prices:see details
DailyMed Link:ZYKADIA at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp
ZYKADIA
ceritinib
CAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Novartis Pharms Corp
ZYKADIA
ceritinib
CAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Novartis Pharms Corp
ZYKADIA
ceritinib
CAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Novartis Pharms Corp
ZYKADIA
ceritinib
CAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Novartis Pharms Corp
ZYKADIA
ceritinib
CAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Novartis Pharms Corp
ZYKADIA
ceritinib
CAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
ZYKADIA
ceritinib
CAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
ZYKADIA
ceritinib
CAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Novartis Pharms Corp
ZYKADIA
ceritinib
CAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Novartis Pharms Corp
ZYKADIA
ceritinib
CAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ZYKADIA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,557,806Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds► Subscribe
8,957,081Compounds and compositions as protein kinase inhibitors► Subscribe
8,822,6852,4-pyrimidinediamine compounds and their uses► Subscribe
7,642,3512,4-Pyrimidinediamine compounds and their uses► Subscribe
7,557,2102,4-pyrimidinediamine compounds and their uses► Subscribe
7,517,886Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds► Subscribe
7,803,9392,4-pyrimidinediamine compounds and their uses► Subscribe
8,263,590Pyrimidine derivatives► Subscribe
9,540,3342,4-pyrimidinediamine compounds and their uses► Subscribe
7,329,6722,4-pyrimidinediamine compounds and their uses► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ZYKADIA

Country Document Number Estimated Expiration
European Patent Office2651918► Subscribe
Israel221381► Subscribe
Guatemala201300153► Subscribe
South Africa200405979► Subscribe
Australia2003265336► Subscribe
European Patent Office3012249► Subscribe
Argentina045458► Subscribe
Mexico2010002336► Subscribe
Russian Federation2008147305► Subscribe
Israel173129► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ZYKADIA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
785Luxembourg► SubscribePRODUCT NAME: CERITINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI. FIRST REGISTRATION: 20150508
0150037 00157Estonia► SubscribePRODUCT NAME: TSERITINIIB;REG NO/DATE: EU/1/15/999 08.05.2015
15/047Ireland► SubscribePRODUCT NAME: CERITINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION: IRELAND EU/1/15/999 (C(2015) 3218), 20150506
2015 00050Denmark► SubscribePRODUCT NAME: CERITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/15/999 20150508
2015034,C2091918Lithuania► SubscribePRODUCT NAME: CERITINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/15/999 20150506
7 5020-2015Slovakia► SubscribePRODUCT NAME: CERITINIB; REGISTRATION NO/DATE: EU/1/15/999 20150508
2015 00047Denmark► SubscribePRODUCT NAME: CERITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/15/999 (C(2015)3218) 20150506
C0058France► SubscribePRODUCT NAME: CERITINIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/15/999 20150508
0763Netherlands► SubscribePRODUCT NAME: CERITINIB, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/15/999 20150508
2015 00047Denmark► SubscribePRODUCT NAME: CERITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/15/999 (C(2015)3218) 20150508
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Healthtrust
Cipla
Queensland Health
Johnson and Johnson
UBS
US Department of Justice
McKinsey
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot